Related Experiment Videos
Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction
J P W Heaton1, J Dean, D J Sleep
1Queens University, Kingston, Ontario, Canada. heatonj@post.queens.ca
International Journal of Impotence Research
|March 16, 2002
Summary
Uprima (apomorphine sublingual, apo SL) offers a consistent and durable response for erectile dysfunction. Optimal benefits are achieved with repeat dosing, with patients encouraged to try at least four 3 mg doses.
Area of Science:
- Pharmacology
- Urology
- Clinical Trials
Background:
- Uprima (apomorphine sublingual, apo SL) is a well-documented treatment for erectile dysfunction.
- Previous trials show apo SL provides a predictable, consistent, and durable response in diverse patient populations.
Purpose of the Study:
- To evaluate the impact of sequential dosing on treatment outcomes.
- To determine the optimal dosage and administration frequency for Uprima.
Main Methods:
- Analysis of clinical trial data to assess treatment response.
- Calculation of the impact of persisting with sequential treatment on outcomes.
- Evaluation of efficacy across different dosages and repeat administrations.
Main Results:
- Apomorphine sublingual (apo SL) is effective in 50% of single doses.
- Repeat dosing demonstrates additional clinical benefit, with full effect potentially requiring four or more administrations.
- The 3 mg dosage shows superior activity compared to other doses.
Conclusions:
- Sequential treatment with Uprima (apomorphine sublingual) enhances clinical benefit.
- Patients should be encouraged to use a minimum of four 3 mg doses for optimal outcomes.
- Patient counseling and realistic expectation setting are crucial for successful treatment.